Oportuzumab monatox

Drug Profile

Oportuzumab monatox

Alternative Names: Proxinium; VB-4847; VB-845; VB4-845; Vicinium

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator University of Zurich
  • Developer Eleven Biotherapeutics; Viventia Biotechnologies
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bladder cancer
  • Phase II/III Head and neck cancer
  • No development reported Liver cancer; Ovarian cancer

Most Recent Events

  • 14 Nov 2016 Eleven Therapeutics plans a phase II trial for head and Neck cancer (Combination therapy)
  • 21 Sep 2016 Viventia Biotechnologies has been acquired and merged into Eleven Biotherapeutics
  • 05 Feb 2016 No development reported - Preclinical for Liver cancer in Canada (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top